Starpharma Holdings Limited · ASX:SPL
Starpharma — Australian BioInvestment Forum 2006
35 slides from Starpharma's conference presentation, Jun 14, 2006
Slide 1: Starpharma Holdings Limited - Australian BioInvestment Forum
sph starp aria Starpharma Holdings Limited ASMSP I. USOTC:SPHRY eG Capital io-lnvestment Forum 14 June 2006 Australian Br Jackie Fairley - Chief Operating Officer “Top Nanotech Buys for 2005— “We expect great things to come from the company and its significant ownership in U.S -based Dendritic Nanot
Slide 2: Forward-looking statements
sph starp aria This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance that these expectations will prove to be corr
Slide 3: Outline
sph Guiline starpharma 1. Company Overview VivaGel™ — Product Overview VivaGel™ — Excellent Market Opportunities Pipeline Equity Holding in Dendritic Nanotechnologies Inc oo & wR Conclusion
Slide 4: 1. Company Overview
sph starp aria 7. ty Overview starpharma
Slide 5: Company Overview
© Gompany Overview starpharma » — Starpharma Holdings Limited (‘Starpharma’) (ASX:SPL) is a world leader in the development of nanotechnology based pharmaceuticals (dendrimers) » Starpharma’s lead product, VivaGe/™ is being developed as a microbicide to prevent the sexual transmission of HIV and Gen
Slide 6: 2. VivaGel Product Overview
sok starp aria 2. Vival Preduct Overview starpharma
Slide 7: VivaGel - Lead Product for Prevention of HIV
@ VivaGer™ —~ Lead Product for Prevertion of &Vis starpharma VivaGel™ package ‘0 pre-filled applicators. « VivaGel™ is a microbicide being developed to prevent sexually transmitted infections (STIs) in women » VivaGel™ is a gel-based formulation with a nanotech active, delivered privately via an app
Slide 8: HIV - A Preventable, Life Threatening Disease
@ HIV -A Preventable, Lite Threatening Disease starpharma » — Human Immunodeficiency Virus (HIV) is the virus that causes AIDS (Acquired Immune Deficiency Syndrome) * No cure for HIV/AIDS and may be transmitted by individuals that are asymptomatic * 39 million people living with HIV; every day 7,000
Slide 9: Genital Herpes - Nasty, Incurable Disease
@ Genital Hermes - Nasty, incurable Disease starpharma Genital herpes is the “un-recognised pandemic” of the industrialised world ~ 22% of the US adult population has genital herpes; Est. cost (US) >$1.5B pa Without intervention the prevalence of genital herpes in the US is expected to increase to 3
Slide 10: VivaGel - Product Features and Performance
@ VivaGel™ — Product Features and Performance starpharma Product Offers Market research indicates microbicide gels will have good uptake Several Key Female controlled, discreet and convenient Advantages Compelling competitive advantages: efficacy; non-irritant; broad activity* Compatible with condom
Slide 11: VivaGel - Significance of NIH Support & Fast Track Status
e VivaGel™ . Significance of MIM support& Past Track Status starpharma « Funding is provided without downstream commercial obligations US$20.3m + of non- Ue lege li |= Funding will allow Starpharma to take product to market itself or US-based NIH secure a late-stage licensing deal « NIH funding will
Slide 12: VivaGel - Development Path
e VivaGer™ — Development Path starpharma MICROBICIDES Development DEVELOPMENT PATH path for SPL.LEAD PRODUCTS DEVELOPMENT PLAN (Prevention) microbicides 1H, 2008 2H, 2008 4H, 2007 2H, 2007 41H, 2008 2H, 2008 Tule and toerabl differs from that é i 4 i a > eS of other drugs VivaGel™ HIV Prevention i :
Slide 13: VivaGel - Potent Contraceptive Activity in Rabbits
ce VivaGel™ » Potent Contraceptive Activity in Rabbits starpharma * Recent study has shown that SPL7013, the active ingredient in Average No. of Embryos Conceived Per Animal Following its VivaGel ™, exhibits a potent Application of Vaginal Gels, and % Relative Fertilityin contraceptive effect in rab
Slide 14: 3. VivaGel Excellent Market Opportunities
sph starp aria 3. Viva Excellent Market Opportunities starpharma
Slide 15: Commercial Opportunity for Microbicides
e Commercial Opportunity for Microbicides starpharma » Large, addressable markets: ~ HIV primarily in developing countries ~ HSV-2 in both developing and developed countries s Increasing market “pull’ for products ~ US government firmly committed to development of safe and effective microbicides ({M
Slide 16: VivaGel - Line Extensions
VivaGelr™ — Line Extensions sph starp aria Condom Coatings ComboGel The most common coating in premium condoms is nonxynol-9 (N-9) that is meant to provide spermicidal protection and act as a microbicide Recent studies have shown that the detergent N-9 actually results in an increase in the rate of
Slide 17: Pipeline
sph starp aria starpharma
Slide 18: Applications of Dendrimers in Life Sciences
e Applications of Beadrimers in Lite Sciences starpharma Pharmaceuticals — Polyvalent = multivalent presentation of covalently bound surface groups; activity due to multiple presentation of surface groups — “Re-engineering” and/or re-formulation of existing drugs (technical & life-cycle management)
Slide 19: Starpharma's Pipeline
@ Starpharma’s Pipeline starpharma Development Pipeline VivaGel™. HIV aS VivaGel™. Herpes SS ‘ComboGel’ -_o > 05/06: 3 new patents filed Condom Coating —— PS ss as ss ADME’ Engineering ee ee Anti-Cancer Agent an Anti-angiogenesis/AMD a ee a o omen | I In-vive Diagnostic GPCR Agonists L ] | J I I , F
Slide 20: Equity Holding in Dendritic Nanotechnologies
sph starp aria
Slide 21: Dendritic Nanotechnologies Inc (DNT)
@ Bendritie Nanotechnologies ine. (ONT) starpharma MCaps of Listed US Nanomaterials Companies « SPL has a 33% holding in a private US company DNT (The DOW Chemical Company holds 30% DNT equity) « DNT has existing revenues streams from deals with leading companies including Pfizer Inc; Sigma Aldrich;
Slide 22: DNT: Wider Exploitation of Dendrimers
starpharma ONT? Wider Exploitation of Dendrimers ~ Initiatives Status & Funding Lead Candidate Screening - National Cancer Institute contract ($850k) » Small Business Administration grant (2220 k) NCL Collaboration Receptor targeted Diagnostic for Ovarian Cancer Receptor targeted Lead Candidate Scre
Slide 23: DNT: Exploiting Dendrimer Properties
OMT: Exploiting deadrimer properties starpharma Dendrimers offer the potential for: = Increased drug solubility = Reduced drug toxicity « Increased cellular retention times « Attachment of targeting moieties = Product life-cycle management ‘Solubility Enhancement of Indomethacin and Paclitaxel Prios
Slide 24: DNT's Business Partners
@ Siar harma ____| DNT’s Business Partners | at starpharma ee) <> vo DHARMACON QIAGEN Mrincuesiaari ees THE NATIONAL DENDRIM| BARGTECOREL OGY GENER a2 COLUMBIA UNIVERSITY NSTTUTE PORE lumera @ atoricer SULLIVAN 24
Slide 25: 6. Conclusion
sph starp aria 6. starpharma
Slide 26: Starpharma: Investment Highlights
Starpharma: investment Mighttglits sph starp aria Strong Financial Position: v Track Record Of Delivery/ =” Internationally Recognised Clinical Program: v Additional Commercial v Opportunities: v A$15.4M cash (March 2006) US$26m* non-diluting funding from the NIH (off balance sheet) for VivaGel™ for
Slide 27: For Further Information
sph starp aria For Further (nformationz
Slide 28: Appendices
sph starp aria starpharma
Slide 29: Starpharma's ADR Program
Starpharna’s AOR program sph starp aria DRs Outstanding & DR Mkt Cap - (Feb 2005 - Feb 2006) 1,000,000) 600,000 Bke Outstanding Commenced: Issued by: DRs Outstanding: ADRs: Major brokers: $4,000,000 $3,000,000 o 8 $2 000 000 2 4 C00 cnc — $0 Feb 2005 Apr 2008 Jun 2005 Aug 2005 Oct 2005 Dee 2005 Feb
Slide 30: Starpharma is a Leader in Nanopharmaceuticals
e Starnharmna is a Leader in Nanopharmaceuticals” starpharma » Nanotechnology is the manipulation of matter smaller than 100 nanometres (‘nm’) » Starpharma is a leader in developing dendrimers as drugs (VivaGel™ represented the first IND for a dendrimer) THE NANOSCALE + > * _Dendrimers are highly br
Slide 31: Dendrimers - Precise Nanoscale Synthetic Chemistry
@ Dendrimers - Precise Nanoscale Synthetic Chemistry starpharma 31
Slide 32: Dendrimers - a Platform for Polyvalent Interactions
Dendrimers —-a Platform for Polyvalent interactions starpharma Dendrimer nanodrug-recepter polyvalent interaction, mimics nature, and results in potentially enhanced activity compared with small molecules. Traditional monovalent drug- receptor interaction. a ph starp arma
Slide 33: VivaGel - What is the Product Concept?
VivaGel™ — What is the Product Goncept? starpharma a starpharma 33
Slide 34: VivaGel - Excellent Market Opportunities
e VivaGer™ — Excellent Market Qupertunities starpharma Developed Countries: Average Frequency of Use per Annum Market Penetration » Key assumptions — 291m women of reproductive age (15-49) in developed countries — Unit sale price circa US$2 — Usage rates according to published data 34
Slide 35: VivaGel - Significant Advantages Over Competitors
VivaGel™ — Significant Advantages Over Competitors starpharma Competitor Category Key Disadvantages VivaGel'” Advantages Significant Advantages over Other Products in Development tection as mono-therapy? 35
Starpharma Holdings — Australian BioInvestment Forum 2006 on 6ix